Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 81

1.

Identification of Incidental Germline Mutations in Patients With Advanced Solid Tumors Who Underwent Cell-Free Circulating Tumor DNA Sequencing.

Slavin TP, Banks KC, Chudova D, Oxnard GR, Odegaard JI, Nagy RJ, Tsang KWK, Neuhausen SL, Gray SW, Cristofanilli M, Rodriguez AA, Bardia A, Leyland-Jones B, Janicek MF, Lilly M, Sonpavde G, Lee CE, Lanman RB, Meric-Bernstam F, Kurzrock R, Weitzel JN.

J Clin Oncol. 2018 Oct 19:JCO1800328. doi: 10.1200/JCO.18.00328. [Epub ahead of print]

PMID:
30339520
2.

TumorNext-Lynch-MMR: a comprehensive next generation sequencing assay for the detection of germline and somatic mutations in genes associated with mismatch repair deficiency and Lynch syndrome.

Gray PN, Tsai P, Chen D, Wu S, Hoo J, Mu W, Li B, Vuong H, Lu HM, Batth N, Willett S, Uyeda L, Shah S, Gau CL, Umali M, Espenschied C, Janicek M, Brown S, Margileth D, Dobrea L, Wagman L, Rana H, Hall MJ, Ross T, Terdiman J, Cullinane C, Ries S, Totten E, Elliott AM.

Oncotarget. 2018 Apr 17;9(29):20304-20322. doi: 10.18632/oncotarget.24854. eCollection 2018 Apr 17.

3.

TumorNext: A comprehensive tumor profiling assay that incorporates high resolution copy number analysis and germline status to improve testing accuracy.

Gray PN, Vuong H, Tsai P, Lu HM, Mu W, Hsuan V, Hoo J, Shah S, Uyeda L, Fox S, Patel H, Janicek M, Brown S, Dobrea L, Wagman L, Plimack E, Mehra R, Golemis EA, Bilusic M, Zibelman M, Elliott A.

Oncotarget. 2016 Oct 18;7(42):68206-68228. doi: 10.18632/oncotarget.11910.

4.

Hypercalcemia from metastatic pancreatic neuroendocrine tumor secreting 1,25-dihydroxyvitamin D.

Zhu V, de Las Morenas A, Janicek M, Hartshorn K.

J Gastrointest Oncol. 2014 Aug;5(4):E84-7. doi: 10.3978/j.issn.2078-6891.2014.042.

5.

Phase I trial of intraperitoneal pemetrexed, cisplatin, and paclitaxel in optimally debulked ovarian cancer.

Chambers SK, Chow HH, Janicek MF, Cragun JM, Hatch KD, Cui H, Laughren C, Clouser MC, Cohen JL, Wright HM, Abu Shahin N, Alberts DS.

Clin Cancer Res. 2012 May 1;18(9):2668-78. doi: 10.1158/1078-0432.CCR-12-0261. Epub 2012 Mar 15.

6.

Phase III trial of induction gemcitabine or paclitaxel plus carboplatin followed by paclitaxel consolidation in ovarian cancer.

Gordon AN, Teneriello M, Janicek MF, Hines J, Lim PC, Chen MD, Vaccarello L, Homesley HD, McMeekin S, Burkholder TL, Wang Y, Zhao L, Orlando M, Obasaju CK, Gill JF, Tai DF.

Gynecol Oncol. 2011 Dec;123(3):479-85. doi: 10.1016/j.ygyno.2011.08.018. Epub 2011 Oct 5.

PMID:
21978765
7.

Anatomic differences after robotic-assisted radical prostatectomy and open prostatectomy: implications for radiation field design.

Hirsch AE, Cuaron JJ, Janicek MJ, Mui K, Lee RJ, Wang DS, Babayan RK, Zumwalt AC, Gignac GA, Tao W, Ozonoff A, Zietman AL.

Pract Radiat Oncol. 2011 Apr-Jun;1(2):115-25. doi: 10.1016/j.prro.2010.11.007. Epub 2011 Apr 8.

PMID:
24673925
8.

Pilot study of the prospective identification of changes in cognitive function during chemotherapy treatment for advanced ovarian cancer.

Hess LM, Chambers SK, Hatch K, Hallum A, Janicek MF, Buscema J, Borst M, Johnson C, Slayton L, Chongpison Y, Alberts DS.

J Support Oncol. 2010 Nov-Dec;8(6):252-8.

PMID:
21265392
9.

Overexpression of tumor vascular endothelial growth factor A may portend an increased likelihood of progression in a phase II trial of bevacizumab and erlotinib in resistant ovarian cancer.

Chambers SK, Clouser MC, Baker AF, Roe DJ, Cui H, Brewer MA, Hatch KD, Gordon MS, Janicek MF, Isaacs JD, Gordon AN, Nagle RB, Wright HM, Cohen JL, Alberts DS.

Clin Cancer Res. 2010 Nov 1;16(21):5320-8. doi: 10.1158/1078-0432.CCR-10-0974.

10.

Dynamic infrared imaging of newly diagnosed malignant lymphoma compared with Gallium-67 and Fluorine-18 fluorodeoxyglucose (FDG) positron emission tomography.

Janicek MJ, Demetri G, Janicek MR, Shaffer K, Fauci MA.

Technol Cancer Res Treat. 2003 Dec;2(6):571-8.

PMID:
14640768
11.

Phase I clinical trial of recombinant human endostatin administered as a short intravenous infusion repeated daily.

Eder JP Jr, Supko JG, Clark JW, Puchalski TA, Garcia-Carbonero R, Ryan DP, Shulman LN, Proper J, Kirvan M, Rattner B, Connors S, Keogan MT, Janicek MJ, Fogler WE, Schnipper L, Kinchla N, Sidor C, Phillips E, Folkman J, Kufe DW.

J Clin Oncol. 2002 Sep 15;20(18):3772-84.

PMID:
12228197
12.

Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors.

Demetri GD, von Mehren M, Blanke CD, Van den Abbeele AD, Eisenberg B, Roberts PJ, Heinrich MC, Tuveson DA, Singer S, Janicek M, Fletcher JA, Silverman SG, Silberman SL, Capdeville R, Kiese B, Peng B, Dimitrijevic S, Druker BJ, Corless C, Fletcher CD, Joensuu H.

N Engl J Med. 2002 Aug 15;347(7):472-80.

13.

Rituximab and CHOP induction therapy for newly diagnosed mantle-cell lymphoma: molecular complete responses are not predictive of progression-free survival.

Howard OM, Gribben JG, Neuberg DS, Grossbard M, Poor C, Janicek MJ, Shipp MA.

J Clin Oncol. 2002 Mar 1;20(5):1288-94.

PMID:
11870171
14.

Progressive sclerosis of isolated foot metastasis of prostate cancer.

Oh WK, Loda M, Kantoff PW, Janicek M.

J Urol. 2002 Mar;167(3):1392. No abstract available.

PMID:
11832744
15.

Cervical cancer: prevention, diagnosis, and therapeutics.

Janicek MF, Averette HE.

CA Cancer J Clin. 2001 Mar-Apr;51(2):92-114; quiz 115-8. Review.

16.

Manifestations of toxic lung effects on Ga-67 scans in aggressive non-Hodgkin's lymphoma with high-dose CHOP chemotherapy.

Janicek MJ, Shaffer K.

Clin Nucl Med. 2000 Sep;25(9):734-5. No abstract available.

PMID:
10983770
17.

Meningeal carcinomatosis in lung cancer. Case 2. Carcinomatous meningitis.

Jänne PA, Janicek MJ, Brown F.

J Clin Oncol. 2000 Aug;18(15):2927-9. No abstract available.

PMID:
10920142
18.

Two patients with sarcoma. Case 2. Uterine sarcoma.

Blobe GC, Mantel M, Janicek M, Demetri GD.

J Clin Oncol. 2000 Jun;18(11):2343-4. No abstract available.

PMID:
10829056
19.

Side effects of chemotherapy. Case 3. Acute interstitial pneumonitis related to gemcitabine.

Attar EC, Ervin T, Janicek M, Deykin A, Godleski J.

J Clin Oncol. 2000 Feb;18(3):697-8. No abstract available.

PMID:
10653887
20.

Monitoring therapeutic response in skeletal metastases using dual-energy x-ray absorptiometry: a prospective feasibility study in breast cancer patients.

Shapiro CL, Keating J, Angell JE, Janicek M, Gelman R, Hayes D, LeBoff MS.

Cancer Invest. 1999;17(8):566-74.

PMID:
10592763
21.

Generation of tumor-specific cytotoxic T lymphocytes by stimulation with HPV type 16 E7 peptide-pulsed dendritic cells: an approach to immunotherapy of cervical cancer.

Schoell WM, Mirhashemi R, Liu B, Janicek MF, Podack ER, Penalver MA, Averette HE.

Gynecol Oncol. 1999 Sep;74(3):448-55.

PMID:
10479508
22.

Critical care issues in cervical cancer management.

Mirhashemi R, Janicek MF, Schoell WM.

Semin Surg Oncol. 1999 Apr-May;16(3):267-74. Review.

PMID:
10225307
23.

Epidemiology and biology of cervical cancer.

Schoell WM, Janicek MF, Mirhashemi R.

Semin Surg Oncol. 1999 Apr-May;16(3):203-11. Review.

PMID:
10225296
24.

Close vaginal margins as a prognostic factor after radical hysterectomy.

Estape RE, Angioli R, Madrigal M, Janicek M, Gomez C, Penalver M, Averette H.

Gynecol Oncol. 1998 Mar;68(3):229-32.

PMID:
9570971
25.

Significance of intraperitoneal cytology in patients undergoing radical hysterectomy.

Estape R, Angioli R, Wagman F, Madrigal M, Janicek M, Ganjei-Azar P, Penalver M, Averette H.

Gynecol Oncol. 1998 Feb;68(2):169-71.

PMID:
9514813
26.

Tumor angiogenesis as a prognostic factor in ovarian carcinoma: quantification of endothelial immunoreactivity by image analysis.

Schoell WM, Pieber D, Reich O, Lahousen M, Janicek M, Guecer F, Winter R.

Cancer. 1997 Dec 15;80(12):2257-62.

PMID:
9404702
27.

Use of lonidamine to potentiate the effect of cisplatin and carboplatin on platinum resistant human ovarian cancer cells.

Angioli R, Janicek M, Sevin B, Estape R, Averette H, Koechli O, Untch M, Penalver M.

Int J Oncol. 1997 Oct;11(4):777-80.

PMID:
21528274
28.

p53 interference and growth inhibition in p53-mutant and overexpressing endometrial cancer cell lines.

Janicek MF, Angioli R, Unal AD, Sevin BU, Madrigal M, Estape R, Averette HE.

Gynecol Oncol. 1997 Jul;66(1):94-102.

PMID:
9234928
29.

Hypertrophic osteoarthropathy.

Burstein HJ, Janicek MJ, Skarin AT.

J Clin Oncol. 1997 Jul;15(7):2759-60. No abstract available.

PMID:
9215850
30.

Advanced mucinous adenocarcinoma in pregnancy.

Angioli R, Yasin S, Estape R, Janicek M, Adra A, Sopo C, Minhaj M, Penalver M.

Oncol Rep. 1997 May-Jun;4(3):501-3.

PMID:
21590085
31.

Early restaging gallium scans predict outcome in poor-prognosis patients with aggressive non-Hodgkin's lymphoma treated with high-dose CHOP chemotherapy.

Janicek M, Kaplan W, Neuberg D, Canellos GP, Shulman LN, Shipp MA.

J Clin Oncol. 1997 Apr;15(4):1631-7.

PMID:
9193363
32.

In vitro antigene therapy targeting HPV-16 E6 and E7 in cervical carcinoma.

Madrigal M, Janicek MF, Sevin BU, Perras J, Estape R, Peñalver M, Averette HE.

Gynecol Oncol. 1997 Jan;64(1):18-25.

PMID:
8995542
33.

Bone lymphoma. Comparison of Tl-201 and Ga-67 citrate scintigraphy in assessment of treatment response.

Roach PJ, Janicek MJ, Kaplan WD.

Clin Nucl Med. 1996 Sep;21(9):689-94.

PMID:
8879868
34.

Mediastinal tumor presenting as a cardiac halo on equilibrium radionuclide angiography. A differential diagnosis to pericardial effusion.

Better N, Janicek MJ, Annese ML, Kaplan WD.

Clin Nucl Med. 1996 Apr;21(4):334-5. No abstract available.

PMID:
8925627
35.

High-dose CHOP as initial therapy for patients with poor-prognosis aggressive non-Hodgkin's lymphoma: a dose-finding pilot study.

Shipp MA, Neuberg D, Janicek M, Canellos GP, Shulman LN.

J Clin Oncol. 1995 Dec;13(12):2916-23.

PMID:
8523055
36.
37.

Combination anti-gene therapy targeting c-myc and p53 in ovarian cancer cell lines.

Janicek MF, Sevin BU, Nguyen HN, Averette HE.

Gynecol Oncol. 1995 Oct;59(1):87-92.

PMID:
7557622
38.
39.
40.

Healing flare in skeletal metastases from breast cancer.

Janicek MJ, Hayes DF, Kaplan WD.

Radiology. 1994 Jul;192(1):201-4.

PMID:
8208938
41.

Invasive endometrial cancer in uteri resected for atypical endometrial hyperplasia.

Janicek MF, Rosenshein NB.

Gynecol Oncol. 1994 Mar;52(3):373-8.

PMID:
8157194
42.

Tc-99m HMPAO brain perfusion SPECT in acute aphasia. Correlation with clinical and structural findings.

Janicek MJ, Schwartz RB, Carvalho PA, Garada B, Holman BL.

Clin Nucl Med. 1993 Dec;18(12):1032-8.

PMID:
8293621
43.
44.

Regional cerebral perfusion in Landau-Kleffner syndrome and related childhood aphasias.

O'Tuama LA, Urion DK, Janicek MJ, Treves ST, Bjornson B, Moriarty JM.

J Nucl Med. 1992 Oct;33(10):1758-65.

45.

Quantitative evaluation of 99mTc-hexamethylpropylenamineoxime brain SPECT in childhood-onset epilepsy.

Janicek MJ, O'Tuama LA, Treves ST.

J Nucl Biol Med. 1992 Oct-Dec;36(4):319-23.

PMID:
1296771
46.

Arterial response to ketanserin and aspirin in patients with advanced peripheral atherosclerosis.

Janicek MJ, Meyerovitz M, Harrington DP, Hollenberg NK.

Invest Radiol. 1992 Jun;27(6):415-21.

PMID:
1607256
47.

201Tl/99mTc-HMPAO SPECT imaging of treated childhood brain tumors.

O'Tuama LA, Janicek MJ, Barnes PD, Scott RM, Black PM, Sallan SE, Tarbell NJ, Kupsky WJ, Wagenaar D, Ulanski JS, et al.

Pediatr Neurol. 1991 Jul-Aug;7(4):249-57.

PMID:
1930415
48.

Embolization of platelets after endothelial injury to the aorta in rabbits. Assessment with 111indium-labeled platelets and angiography.

Janicek MJ, Van den Abbeele AD, DeSisto WC, Kassis AI, Holman BL, Tumeh SS, Hollenberg NK.

Invest Radiol. 1991 Jul;26(7):655-9.

PMID:
1885272
49.

Platelet activation and aggregation after endothelial injury. Assessment with indium-111-labeled platelets and angiography.

Janicek MJ, Van den Abbeele AD, Hollenberg NK, Kassis AI, Holman BL, Tumeh SS.

Invest Radiol. 1990 Sep;25(9):988-93.

PMID:
2211057
50.

Atherosclerosis, peripheral arterial disease and the vascular response to ketanserin.

Janicek M, Grassi CJ, Meyerovitz M, Callahan MB, Sandor T, Whittemore A, Mannick J, Harrington DP, Hollenberg NK.

Invest Radiol. 1990 May;25(5):495-503.

PMID:
2345079

Supplemental Content

Loading ...
Support Center